Abstract
Abstract
Purpose
To assess the real-world prevalence of microsatellite instability (MSI)/mismatch repair (MMR) testing and related tumor status in recurrent/advanced endometrial cancer patients in Europe.
Methods
Data were from two multi-center, retrospective patient chart review studies conducted in the United Kingdom, Germany, Italy, France and Spain: The Endometrial Cancer Health Outcomes-Europe-First-Line (ECHO-EU-1L) study and the ECHO-EU-Second-Line (ECHO-EU-2L) study. ECHO-EU-1L included recurrent/advanced endometrial cancer patients who received first-line systemic therapy between 1/JUN/2016 and 31/MAR/2020 after recurrent/advanced diagnosis. ECHO-EU-2L included patients with recurrent/advanced endometrial cancer who progressed between 1/JUN/2016 and 30/JUN/2019 following prior first-line systemic therapy. Data collected included patient demographics, MSI/MMR tumor testing and results, and clinical/treatment characteristics.
Results
ECHO-EU-1L included 242 first-line patients and ECHO-EU-2L included 475 s-line patients. For all patients, median age at recurrent/advanced diagnosis was 69 years, roughly half had endometrioid carcinoma histology and over 75% had Stage IIIB-IV disease at initial diagnosis. The prevalence of MSI/MMR testing in the first-line and second-line cohorts was similar (36.4 and 34.9%, respectively). Among those tested, a majority had non-MSI-high/MMR proficient tumors (80.7 and 74.7% among first- and second-line patients, respectively). About 15% had MSI-high/MMR deficient tumors in both cohorts, and a few patients had discordant results (3.4 and 10.8% among first- and second-line patients, respectively).
Conclusion
Prior to the approvals of biomarker-directed therapies for recurrent/advanced endometrial cancer patients in Europe, there were low MSI/MMR testing rates for these patients of just over one-third. Given the availability of biomarker-directed therapies, increased MSI/MMR testing may help inform treatment decisions for recurrent/advanced endometrial cancer patients in Europe.
Publisher
Springer Science and Business Media LLC
Reference21 articles.
1. Zhang S, Gong TT, Liu FH et al (2019) Global, regional, and national burden of endometrial cancer, 1990–2017: results from the global burden of disease study. Front Oncol 9:1440. https://doi.org/10.3389/fonc.2019.01440
2. (2020) The global cancer observatory Corpus uteri—international agency for research on cancer Corpus uteri. https://gco.iarc.fr/today/data/factsheets/cancers/24-Corpus-uteri-fact-sheet.pdf. Published December 2020. Accessed December 13, 2022.
3. Creasman WT, Odicino F, Maisonneuve P et al (2006) Carcinoma of the corpus uteri. Int J Gynaecol Obstet 95(Suppl 1):S105–S143. https://doi.org/10.1016/S0020-7292(06)60031-3
4. Ries LAG, Young JL, Keel GE, Eisner MP, Lin YD, Horner M-J (2007) SEER survival monograph: cancer survival among adults: U.S. SEER program, 1988-2001, patient and tumor characteristics. Bethesda, MD, National Cancer Institute, SEER Program. https://seer.cancer.gov/archive/publications/survival/seer_survival_mono_lowres.pdf
5. Huijgens AN, Mertens HJ (2013) Factors predicting recurrent endometrial cancer. Facts Views Vis Obgyn 5(3):179–186
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献